14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ETON vs DMAC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ETON carries a Unified Composite Score of 36.5/100 (SELL) at $64.30 (19.3x Forward P/E, 31.3% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While DMAC currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. ETON 36.5/100 SELL), ETON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (31.3% vs. 0.0% operating margin) and revenue trajectory (+157.9% vs. +0.0% YoY).
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ETON vs DMAC Key Questions & Quantitative Answers
As of Nov 16, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ETON carries a Unified Composite Score of 36.5/100 (SELL) at $64.30 (19.3x Forward P/E, 31.3% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DMAC currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. ETON 36.5/100 SELL), ETON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (31.3% vs. 0.0% operating margin) and revenue trajectory (+157.9% vs. +0.0% YoY).
ETON leads the Growth & Scale pillar: ETON posts +157.9% YoY revenue growth and -12.6% YoY earnings growth on $141M TTM revenue (71.2% gross margin, 31.3% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ETON cumulative revenue shifted +300.0% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, ETON deploys 39.9% of Rev ($56M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.
ETON screens cheaper on headline valuation multiples. ETON trades at 19.3x Forward P/E, 39.9x Trailing P/E, N/M PEG, and 12.3x EV/Revenue (14.2% FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ETON (90.6% ROE) versus DMAC (-114.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ETON carries 59.3% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.63β · 99% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.